MammaPrint BluePrint illuminating tumor biology

MammaPrint + BluePrint answer multiple clinical questions in just 6 days from core biopsy to optimize treatment in patients with HR+/HER2- early-stage breast cancer.

Genomic Insights That Guide Ten Years of Personalized Treatment in Early-Stage Breast Cancer

Pathological response

Discuss the data with your local Agendia MOS & MSL

Request Data Review / Additional Data:
* indicates required
Select the data you would like to learn more about